May 08, 2025

FDA Warns Physicians of Tianeptine Dangers

The FDA warns physicians about unapproved tianeptine products that are linked to severe adverse events, including dependence, toxicity, and death.

Conexiant

May 08, 2025

SGLT2 Inhibitors Lower Hyperkalemia Risk in Patients Taking RAASi 

Researchers found that starting SGLT2 inhibitors in older patients on RAAS inhibitors reduced the risk of hyperkalemia and helped more patients stay on RAAS therapy.

Conexiant

May 07, 2025

FDA Approves Low-Dose Chlorthalidone Tablet

The FDA has approved HemiClor, a 12.5-mg chlorthalidone tablet, providing patients with a low-dose option.

Conexiant

May 06, 2025

FDA Approves TAVR Platform for Asymptomatic AS

The FDA has approved the SAPIEN 3 TAVR platform for patients with asymptomatic severe aortic stenosis based on data from the EARLY TAVR trial.

Conexiant

May 06, 2025

Anemia Linked to Hidden Heart Strain in RA

A new study found that 1 in 3 rheumatoid arthritis patients with normal heart function on standard tests had hidden heart strain detectable only through advanced imaging, with anemia emerging as the strongest predictor.

Conexiant

May 05, 2025

True Heart Age Beyond Birthdays

New research uses cardiac MRI to calculate "functional heart age," showing obesity and other risk factors can age the heart by decades.

Conexiant

May 01, 2025

Phthalates Linked to Cardiovascular Mortality Globally

Researchers linked di-2-ethylhexylphthalate plastic exposure to over 350,000 cardiovascular deaths and 10 million years of life lost, supporting calls for international regulatory measures.

Conexiant

May 01, 2025

Modifiable Risk Factors Linked to Sudden Cardiac Arrest Incidence

A UK Biobank analysis identified 56 modifiable risk factors for sudden cardiac arrest; lifestyle improvements alone could prevent up to 18% of cases, with a total prevention potential of 63%.

Conexiant

April 30, 2025

New Phase III Data: Sotatercept for PAH

Sotatercept reduced the composite risk of death, lung transplantation, or hospitalization for worsening pulmonary arterial hypertension by nearly 75% compared with placebo in high-risk patients in a phase III trial.

Conexiant